

Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 BioConnect Virtual Conference on January 10-13

SALT LAKE CITY, Jan. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (**Nasdaq-CM: CODX**) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be featured at the H.C. Wainwright & Co. 2022 BioConnect Conference, being held virtually on January 10-13.

Dwight Egan, Company CEO, will be conducting an On-Demand presentation discussing recent Company events related to its forthcoming point-of-care and at-home diagnostic platform, and acquisition of the entities previously working with Co-Diagnostics on the development of the platform. The presentation can be accessed on the [Events and Webcasts](#) section of the Co-Diagnostics website beginning January 10, 2022 at 7:00 am Eastern Time for institutional investors who have [registered](#) for the event.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: our products may not prove to be as effective as other products currently being commercialized or to be commercialized in the future by competitors; risks inherent in manufacturing and scaling up to commercial quantities while maintaining quality controls; the uncertainties inherent in new product development, including the cost and time required to gain regulatory clearance for such product and to commercialize such product(s); and, market acceptance of our products once commercialized.

Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in the Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 25, 2021, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

SOURCE Co-Diagnostics

For further information: Andrew Benson, Head of Investor Relations, +1 801-438-1036, investors@codiagnostics.com; Zach Mizener, Lambert & Co., +1 616-233-0500, zmizener@lambert.com

<https://news.codiagnostics.com/2022-01-10-Co-Diagnostics,-Inc-to-Participate-in-the-H-C-Wainwright-2022-BioConnect-Virtual-Conference-on-January-10-13>